Skin Disease Report
Many skin diseases in the population aged 65 years old and older
are related to lifelong cumulative sun exposure (eg, actinic damage and skin
cancer), and increasing susceptibility to bacterial, viral, and fungal
diseases. By 2030, the US population aged 65 years and older is estimated
to grow by 30 million individuals, and to steadily increase through 2050, with
a projected total population aged 65 years and older of 85 million. Growth
in national health expenditures is projected to double between 2013 and 2020. With
the physician workforce projected to remain relatively flat, the specific ratio
of dermatologists to population will decrease over time, especially in rural
areas. These projections indicate a current and future challenge to ensure
patient access to appropriate dermatologic care.
The cost for individual skin diseases varied widely, partially because
of differences in prevalence, but also because of the cost of medical and
surgical treatment options. Distributed across the entire US population, the
total 2013 health care cost of skin disease was approximately $240 per capita.
Other diseases, such as cardiovascular disease, diabetes, and end-stage renal
disease have significantly higher direct and per affected person costs than
skin disease. However, the per capita costs for these 3 diseases are,
similar to skin disease, less than $1000 (ie, $950 for cardiovascular disease,
$785 for diabetes, and $147 for end-stage renal disease).
Although there are limitations on direct comparison of the previous
AAD/SID BSD report and this current report, it reveals that from 2004 to 2013
there has been a roughly 1.7-fold increase in skin disease health care costs.
Of note, many new and more effective drugs and treatment options for skin
disease were introduced between 2004 and 2013, albeit at higher costs than
older treatments. Examples include new topical medications for acne, biologics
and excimer laser for psoriasis, checkpoint inhibitors for melanoma, and oral
and systemic treatments for cutaneous lymphoma. Since 2013, costs of many
widely used dermatologic medications have increased significantly, and better
understanding of the pathophysiology of diseases has led to development of new
medications. Therefore, the health care cost of skin disease at the time of
writing this article most likely surpasses this 2013 estimation.This report
estimates that the 2013 opportunity cost as a result of skin disease was nearly
$11 billion. Similar to the prevalence and economic BSD, it is also likely that
the opportunity cost may be underestimated, as these estimates are calculated
using claims-based methods. Although it is well recognized that skin diseases
can inflict an enormous toll on the physical and psychosocial well-being of
patients and their families, there is currently a lack of adequate studies on
quality-of-life measures to systematically estimate the costs on a population
level across all skin diseases.
There are limitations to this study. The use of 2013 claims-based
prevalence provides a snapshot in time of the actual health care landscape;
however, it does underestimate the true prevalence of the disease, as it only
accounted those who filed insurance claims in 2013. Furthermore, it limits
direct comparisons with other reports that use differing assessments of
prevalence and disease costs. The health care landscape has rapidly evolved
since 2013; therefore, the true burden at the time of this writing is most
likely higher.
In summary, this article presents an up-to-date US national BSD report
that addresses 24 skin disease categories. Skin disease is a significant and
serious public health consideration for the US population, costing at least $75
billion to treat in a single year. Although this study's approach likely
underestimates overall burden, it ensures consistency in comparing prevalence,
economic, and mortality data across the 24 skin disease categories. With the
projected increase in the age group 65 years and older in the US
population, combined with the increased costs of currently in-use and newly
developed dermatologic treatment options, the economic BSD will continue to
grow. The increased number of individuals older than 65 years, who have
higher skin disease burden, needs to be addressed by an appropriate increase in
dermatologic care providers.
=======================================
Choir (paduan suara) Jaziel and friends sing Close to U
=======================================
=========================
Pokemon Dance Jaziel and friends
=========================
Unduh lagu nasyid
Related Posts:
